Phase IIb Data Showed Merck's Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowered Blood Sugar in Patients with Type 2 Diabetes Merck (NYSE: MRK), known as MSD outside the United ...

Merck MRK announced that it has initiated three separate phase IIb studies evaluating its investigational TL1A inhibitor, tulisokibart (MK-7240), in three new immune-mediated inflammatory diseases.

NEW ORLEANS, LA—An investigational oral PCSK9 inhibitor has shown promise for patients with hypercholesterolemia with a range of atherosclerotic cardiovascular disease (ASCVD) risks in a phase IIb ...

Data Reported at SLEEP 2010 24th Annual Meeting of the Associated Professional Sleep Societies SAN ANTONIO--(BUSINESS WIRE)-- Clinical results from a Phase IIb study showed that MK-4305, Merck's ...

BERLIN--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced Phase IIb data for MK-3102, the company’s investigational once-weekly DPP-4 inhibitor in ...